To include your compound in the COVID-19 Resource Center, submit it here.

Novartis optimizes WNK1 inhibitor hypertension candidate

In a paper published in the Journal of Medicinal Chemistry, researchers from Novartis Institutes of Biomedical Research at

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE